Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
J Clin Pathol. 2018 Jul;71(7):653-658. doi: 10.1136/jclinpath-2017-204828. Epub 2018 Mar 27.
To evaluate peripheral blood (PB) for minimal residual disease (MRD) assessment in adults with acute lymphoblastic leukaemia (ALL).
We analysed 76 matched bone marrow (BM) aspirate and PB specimens independently for the presence of ALL MRD by six-colour flow cytometry (FC).
The overall rate of BM MRD-positivity was 24% (18/76) and PB was also MRD-positive in 22% (4/18) of BM-positive cases. We identified two cases with evidence of leukaemic cells in PB at the time of the extramedullary relapse that were interpreted as MRD-negative in BM.
The use of PB MRD as a non-invasive method for monitoring of systemic relapse may have added clinical and diagnostic value in patients with high risk of extramedullary disease.
评估成人急性淋巴细胞白血病（ALL）外周血（PB）微小残留病（MRD）评估。
我们通过六色流式细胞术（FC）分别分析了 76 对骨髓（BM）抽吸物和 PB 标本，以确定 ALL MRD 的存在。
BM MRD 阳性率为 24%（18/76），BM 阳性病例中有 22%（4/18）的 PB 也是 MRD 阳性。我们发现有 2 例在外髓复发时 PB 中有白血病细胞的证据，而在 BM 中被解释为 MRD 阴性。
将 PB MRD 作为一种非侵入性方法监测全身性复发可能为有髓外疾病高风险的患者增加了临床和诊断价值。
